NARA Discovery
Article Details
← Back to Search Results
Journal Article

Efficacy of Aster chinensis aerial parts metabolites in BALB/c mice model of Imiquimod-induced psoriasis skin inflammation

Mai S. Hendawy; Mona M. Hashem; Ahmed A. Zaki; Mostafa A. Rabie; Nesrine S. El Sayed; Riham Salah El Dine; Ali M. El-Halawany
Inflammopharmacology · Vol. 33, Issue 4 · pp. 1973-1996 · 2025

Abstract

Using a bioassay-guided fractionation approach, the most potent anti-psoriatic components of Aster squamatus herb, Aster chinensis stalks, and Aster chinensis flowers, cultivated in Egypt, were identified and evaluated against Imiquimod (IMQ)-induced psoriasis in female BALB/c mice and compared to standard drug, mometasone. The topical application of A. chinensis stalk methanolic extract exhibited the strongest anti-psoriatic effects against IMQ-induced psoriasis model, as evidenced by improvements in psoriasis area severity index (PASI) score, histopathological analysis, and spleen index. Further fractionation of A. chinensis stalk methanolic extract using petroleum ether, methylene chloride, ethyl acetate, and n -butanol revealed that the methylene chloride fraction (MCF) was the most potent. Indeed, MCF significantly reduced the PASI score, alleviated histopathological changes, and restored spleen index. Mechanistically, MCF exerted its anti-psoriatic effects by suppressing inflammation, evidenced by decreased TLR-4 gene expression and lower levels of HMGB1 and NFκBp65 protein contents. Additionally, MCF reduced serum levels of pro-inflammatory cytokines interleukin (IL)-1β, IL-6, IL-23, and IL-17 while mitigating oxidative stress through increased superoxide dismutase (SOD) activity and reduced malondialdehyde (MDA) content. Notably, the efficacy of MCF was comparable to that of mometasone, with no significant differences observed. In parallel, the chemical profile of the MCF was analyzed using UHPLC-MS/MS techniques in negative and positive ionization full scan modes. MCF of A. chinensis stalk could be used a potential therapeutic agent for psoriasis.

Bibliographic Information

JournalInflammopharmacology
PublisherSpringer
Publication Date2025-04-01
Publication Year2025
Volume33
Issue4
Pages1973-1996
Document TypeJournal Article
Print ISSN0925-4692
eISSN1568-5608
DOI10.1007/s10787-025-01652-x

Access Information

NARA Access Coverage1991-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10787
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.